NCT07062484

A Real-world Study of the Efficacy and Safety of PD-1 Inhibitors Combined With Chemoradiotherapy in Lung Metastatic Nasopharyngeal Carcinoma

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 600 (estimated)
• Sponsor: Sichuan Cancer Hospital and Research Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is a retrospective real-world study. In this study, we plan to collect the clinical data of lung metastatic nasopharyngeal carcinoma patients who received PD-1 inhibitors and chemotherapy combined with or without radiotherapy.

Conditions

• Lung Metastatic Nasopharyngeal Carcinoma

Interventions

Type	Name	Description
DRUG	Control: gemcitabine, cisplatin, tirelizumab	PD-1 inhibitors combined with chemotherapy
DRUG	Experimental: gemcitabine, cisplatin, tirelizumab and radiotherapy	PD-1 inhibitors combined with chemoradiotherapy

Timeline

• Start date: 2025-07-01
• Primary completion: 2025-12-01
• Completion: 2025-12-01
• First posted: 2025-07-14
• Last updated: 2025-07-14

Locations

1 site across 1 country: China